

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Nonspecific Protection Against Lethal Influenza Challenge





Figure 1


Clinical Symptoms Following Intranasal Administration of L-Seryl AGPs



Numbers in parenthesis represent the length of the secondary fatty acid chains.

Figure 2

Clinical Symptoms Following L-Seryl AGPs Monotherapy and Influenza Challenge



Numbers in parentheses represent the percent protection following lethal challenge.

Figure 3




Figure 4A




Figure 4B




Figure 4C




Figure 4D




Figure 5A




Figure 5B




Figure 5C




Figure 5D




Figure 6A




Figure 6B




Figure 6C




Figure 6D




Figure 7A




Figure 7B




Figure 8A




Figure 8B




Figure 8C




Figure 8D




Figure 9A




Figure 9B




Figure 9C






Figure 9D


RC-512




RC-522




RC-524



RC-525



RC-526



RC-527






Figure 10A


RC-529




RC-537




RC-538



RC-540



RC-541



RC-545






Figure 10B


RC-547




RC-554




RC-555



RC-557



RC-558



RC-560






Figure 10C


RC-562




RC-565




RC-566



RC-567



RC-568



RC-569






Figure 10D

RC-570



RC-571



RC-573





Figure 10E



Numbers in parenthesis represent percent survival.

Figure 11

Symptoms Following Influenza Challenge L-Seryl-666 versus L-Seryl-000




Figure 12

Symptoms Following Influenza Challenge




Figure 13

Evaluation of Intravenous Administration of L-Seryl Compounds (1 ug per mouse) as Mediators of Nonspecific Resistance to Intravenous Challenge With *Listeria monocytogenes*




Figure 14

Evaluation of Intravenous Administration of L-Seryl 6 Bar Compounds (1 ug per mouse) as Mediators of Nonspecific Resistance to Intravenous Challenge With *Listeria monocytogenes*




Figure 15

**Evaluation of Intravenous Administration of Various "000" AGP Compounds
(1 ug per mouse) as Mediators of Nonspecific Resistance to Intravenous
Challenge With *Listeria monocytogenes***




Figure 16

**Evaluation of Intravenous Administration of AGP Compounds With Various Linker Lengths
Between the Glucosamine and Aglycon Moieties (1 ug per mouse) as Mediators of
Nonspecific Resistance to Intravenous Challenge With *Listeria monocytogenes***




Figure 17